查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1869787

神经科学抗体和检测市场规模、份额和趋势分析报告：产品、技术、应用、地区和细分市场预测（2025-2033 年）

Neuroscience Antibodies And Assays Market Size, Share & Trends Analysis Report By Product (Consumable, Instrument), By Technology (Immunoassays & Immunochemistry, Molecular diagnostics), By End Use, By Region, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

神经科学抗体和检测市场摘要

2024 年全球神经科学抗体和检测市场规模为 37.2343 亿美元，预计从 2025 年到 2033 年将达到 58.6703 亿美元，复合年增长率为 5.41%。

市场成长的驱动因素是阿兹海默症、帕金森氏症、多发性硬化症、神经发炎和精神疾病等神经系统疾病和神经退化性疾病疾病的日益普遍，这些疾病在全球范围内呈上升趋势。

随着人口老化和诊断技术的进步，对支持疾病早期检测和药物研发的工具的需求日益增长。此外，政府和机构不断加强监管和资金投入，也推动了对关键平台技术（例如抗体和检测方法）的需求，以支持神经科学的研究和开发。政府支出的增加和研发计划的扩展也促进了市场成长。阿兹海默症率的上升是市场扩张的关键驱动因素之一。随着全球人口老化，对早期、精准诊断工具的需求日益增长。根据阿兹海默症协会2024年的预测，美国阿兹海默症患者人数将急剧增加，而且失智症的风险会随着老龄化的增长而增加。预计65岁及以上人口将从2022年的5,800万增加到2050年的8,200万人。婴儿潮世代（1946年至1964年出生）是老年痴呆症失智症风险最高的一代，到2030年，他们都将年满65岁或以上。

此外，技术进步显着改善了多发性硬化症 (MS) 的诊断和监测，为预测期内 MS 诊断市场创造了巨大的成长机会。磁振造影 (MRI)、神经生理监测、智慧型手机应用程式、辅助机器人设备以及经颅直流电刺激 (tDCS) 等神经治疗评估方法等先进技术，均有助于早期检测、患者病患监测和症状管理。推动市场扩张的关键因素之一是全球 MS 发病率的不断上升以及由此产生的对快速准确诊断解决方案的需求。根据国际多发性硬化症联盟 (MS International Federation) 估计，2013 年 MS 患者人数为 230 万，2020 年为 280 万，2023 年为 290 万。

研发投入的不断增加，尤其是在创新成像技术、生物标记检测和数位监测平台开发方面的投入，进一步推动了市场扩张。政府主导的旨在改善诊断服务可近性的措施、技术进步以及医疗基础设施的改善，也是全球多发性硬化症诊断市场成长的推动因素。为了进一步推进神经退化性疾病的研究，贝克曼库尔特诊断公司于2025年1月推出了一系列基于血液的「仅供研究使用（RUO）」生物标记免疫检测。这些检测旨在评估关键生物标记，例如p-Tau217、GFAP、NfL和APOEε4，这些标记正逐渐成为阿兹海默症和其他神经退化性疾病的重要标记物。

贝克曼库尔特推出这项检测方法，彰显了其致力于为研究人员提供尖端仪器的承诺，这些仪器能够以卓越的灵敏度和特异性识别和测量生物标誌物。透过精确测量这些生物标誌物，该检测方法有助于更深入地了解疾病机制，并支持早期诊断技术和个人化治疗方案的开发。此检测方法与贝克曼库尔特的免疫检测分析仪相容，可轻鬆融入现有实验室工作流程，进而提高神经退化性疾病研究的效率和效果。

此外，主要企业推出的新产品正在改善市场供应和竞争格局，从而推动市场扩张。例如，超灵敏生物标记检测公司 Quantelix 于 2022 年 7 月宣布，已完成检查室自建检验(LDT) 的验证，该检测用于定量测量血浆中的磷酸化Tau -181 (pTau-181)。此检测可用于阿兹海默症的诊断评估。此 LDT 采用定量免疫检测测量人类血浆中 pTau-181 的浓度，是美国首个临床应用的此类检测。预计这些用于神经系统疾病的免疫检测诊断技术的进步将在预测期内推动市场更快成长。

同样，2021年11月，Fujirebio Europe NV在其Innotest平台上推出了两款阿兹海默症免疫检测，这是该公司与Adx Neurosciences NV合作以来的首批产品。这两款检测产品旨在测量与突触功能障碍和神经发炎相关的两种生物标记物，而突触功能障碍和神经发炎是阿兹海默症进展的关键过程：神经元五聚蛋白-2 (NPTX2) 和可溶性触发受体表达髓系细胞2 (STREM2)。这些创新可望助力阿兹海默症治疗药物的研发。因此，针对神经科学生物标记的新型免疫检测解决方案的持续推广应用，预计将在未来几年显着推动市场成长。

目录

第一章 神经科学抗体和检测市场：调查方法和范围

2. 神经科学抗体与检测市场：执行摘要

  • 市场概述
  • 产品与技术概览
  • 最终用途简介
  • 竞争格局概览

3. 神经科学抗体和检测市场变数、趋势和范围

  • 市场区隔和范围
  • 市场体系展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
  • 市场驱动因素分析
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 市场限制因素分析
  • 波特五力分析
  • PESTLE分析
  • 管道分析

第四章 神经科学抗体与检测市场：产品估算与趋势分析

  • 神经科学抗体和检测市场：产品差异分析
  • 消耗品
  • 装置

第五章 神经科学抗体与检测市场：技术预测与趋势分析

  • 神经科学抗体与检测市场：技术波动分析
  • 免疫检测和免疫化学
  • 分子诊断
  • 临床化学及其他相关检测平台
  • 其他新兴/超灵敏平台

6. 神经科学抗体和检测市场：终端用途估算和趋势分析

  • 神经科学抗体和检测市场：最终用途差异分析
  • 学术研究机构
  • 诊断实验室
  • 其他的

7. 神经科学抗体与检测市场：区域业务分析

  • 区域市场概况
  • 北美洲
  • 欧洲
  • 亚太地区
  • 拉丁美洲
  • 中东和非洲

第八章 竞争情势

  • 公司分类
  • 策略规划
    • 新产品上市
    • 伙伴关係
    • 获得
    • 合作
    • 资金筹措
  • 主要企业市占率分析，2024 年
  • 公司热力图分析
  • 公司简介
    • Thermo Fisher Scientific
    • Bio-Rad Laboratories, Inc.
    • Merck KGaA
    • F. Hoffmann-La Roche
    • Cell Signaling Technology, Inc.
    • BioLegend, Inc.
    • Exalenz Bioscience Ltd（meridian bioscience）
    • Abcam Plc
    • Rockland Immunochemicals, Inc.
    • GENSCRIPT
    • SANTA CRUZ BIOTECHNOLOGY, INC.
Product Code: GVR-4-68040-764-2

Neuroscience Antibodies And Assays Market Summary

The global neuroscience antibodies and assays market size was valued at USD 3,723.43 million in 2024 and is expected to reach USD 5,867.03 million, growing at a CAGR of 5.41% from 2025 to 2033. The market is driven by the rising prevalence of neurological and neurodegenerative disorders globally-conditions like Alzheimer's, Parkinson's, multiple sclerosis, neuroinflammation, psychiatric disorders, etc.

As populations age and as diagnostic capabilities improve, there is increasing demand for tools that can detect disease earlier and help in drug discovery. Also, regulatory pressures and funding from governments and institutions are growing, which support neuroscience R&D and hence require antibodies/assays as key enabling components. Growth is also being accelerated by rising government spending and R&D projects. One major factor propelling the market's expansion is the increasing incidence of Alzheimer's disease. The need for early and precise diagnostic tools keeps growing as the world's population ages. The 2024 Alzheimer's Association predicts that the number of Americans with Alzheimer's will increase dramatically and that dementia risk increases with age. The number of people 65 and older is expected to increase from 58 million in 2022 to 82 million by 2050. The age group most vulnerable to Alzheimer's dementia, baby boomers (those born between 1946 and 1964), will all be 65 or older by 2030.

Furthermore, technological advancements are greatly improving MS diagnosis and monitoring, and during the forecast period, they are anticipated to generate significant growth opportunities in the MS diagnostics market. Early detection, patient monitoring, and symptom management have all been enhanced by cutting-edge technologies like MRI-based imaging, neurophysiological monitoring, smartphone applications, assistive robotic devices, and neurotherapeutic assessment methods like transcranial direct current stimulation (tDCS). One of the main factors propelling market expansion is the increasing incidence of MS worldwide and the corresponding rise in the need for prompt and precise diagnostic solutions. There were 2.3 million MS patients in 2013, 2.8 million in 2020, and 2.9 million in 2023, according to the MS International Federation.

Increased investment in R&D, especially in the creation of innovative imaging methods, biomarker assays, and digital monitoring platforms, supports market expansion even more. The global MS diagnostics market is also growing as a result of expanding government initiatives to improve access to diagnostic services, technological advancements, and improved healthcare infrastructure. To further the study of neurodegenerative diseases, Beckman Coulter Diagnostics introduced a new line of blood-based Research Use Only (RUO) biomarker immunoassays in January 2025. These tests are intended to evaluate important biomarkers that are becoming important markers in neurodegenerative diseases, such as Alzheimer's disease, including p-Tau217, GFAP, NfL, and APOE ε4.

Beckman Coulter's dedication to giving researchers top-notch instruments to identify and measure biomarkers with remarkable sensitivity and specificity is demonstrated by the launch of these assays. The assays support the development of early diagnostic techniques and individualized treatment plans by providing accurate measurement of these biomarkers, which contributes to a deeper understanding of disease mechanisms. These assays' compatibility with Beckman Coulter's Immunoassay Analyzers guarantees integration with current laboratory workflows, improving the efficacy and efficiency of research on neurodegenerative diseases.

Furthermore, by improving availability and competitive dynamics, major players' introduction of new products has been facilitating market expansion. For instance, the ultrasensitive biomarker detection company Quanterix Corporation announced in July 2022 that a laboratory-developed test (LDT) that measures phospho-Tau 181 (pTau-181) in plasma quantitatively has been validated. This test will aid in the diagnostic evaluation of Alzheimer's disease. This LDT uses a quantitative immunoassay format to measure the levels of pTau-181 in human plasma and was first made available for clinical use in the United States. During the forecast period, the market is expected to grow more quickly due to these developments in immunoassay-based diagnostics for neurological conditions.

Similarly, in November 2021, Fujirebio Europe NV launched two Alzheimer's disease immunoassays on its Innotest platform, marking the first product release following its collaboration with Adx Neurosciences NV. The assays are designed to measure neuronal pentraxin-2 (NPTX2) and soluble triggering receptor expressed on myeloid cells 2 (STREM2), two biomarkers linked to synaptic dysfunction and neuroinflammation key processes associated with Alzheimer's progression. These innovations are expected to complement ongoing therapeutic development efforts for Alzheimer's disease. Consequently, the continued rollout of novel immunoassay solutions targeting neuroscience biomarkers is anticipated to significantly drive market growth over the coming years.

Global Neuroscience Antibodies And Assays Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global neuroscience antibodies and assays market based on product, technology, end use, and region:

  • Product Outlook (Revenue, USD Million, 2021 - 2033)
  • Consumables
  • Instruments
  • Technology Outlook (Revenue, USD Million, 2021 - 2033)
  • Immunoassays & immunochemistry
  • Molecular Diagnostics
  • Clinical Chemistry & other related detection platforms
  • Other emerging / ultrasensitive platforms
  • End Use Outlook (Revenue, USD Million, 2021 - 2033)
  • Academic & Research Institutes
  • Pharmaceutical & Biotechnology Firms
  • Others
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Neuroscience Antibodies and Assays Market: Methodology and Scope

  • 1.1. Market Segmentation and Scope
    • 1.1.1. Segment Definitions
      • 1.1.1.1. Product Segment
      • 1.1.1.2. Technology Segment
      • 1.1.1.3. Sample Product segment
      • 1.1.1.4. End Use Segment
  • 1.2. Regional Scope
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Objectives
    • 1.4.1. Objective - 1
    • 1.4.2. Objective - 2
    • 1.4.3. Objective - 3
  • 1.5. Research Methodology
  • 1.6. Information Procurement
    • 1.6.1. Purchased Database
    • 1.6.2. GVR's Internal Database
    • 1.6.3. Secondary Sources
    • 1.6.4. Primary Research
  • 1.7. Information or Data Analysis
    • 1.7.1. Data Analysis Models
  • 1.8. Market Formulation & Validation
  • 1.9. Model Details
    • 1.9.1. Commodity Flow Analysis
  • 1.10. List of Secondary Sources
  • 1.11. List of Abbreviations

Chapter 2. Neuroscience Antibodies and Assays Market: Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Product and Technology Snapshot
  • 2.3. End Use Snapshot
  • 2.4. Competitive Landscape Snapshot

Chapter 3. Neuroscience Antibodies and Assays Market Variables, Trends, & Scope

  • 3.1. Market Segmentation and Scope
  • 3.2. Market Lineage Outlook
    • 3.2.1. Parent Market Outlook
    • 3.2.2. Related/Ancillary Market Outlook
  • 3.3. Market Dynamics
  • 3.4. Market Drivers Analysis
  • 3.5. Market Dynamics
    • 3.5.1. Market driver analysis
      • 3.5.1.1. Rising incidence of neurological diseases
      • 3.5.1.2. Increasing research and development activities
      • 3.5.1.3. Growth in the pharmaceutical and biotechnology industries
    • 3.5.2. Market restraint analysis
      • 3.5.2.1. High cost of diagnostics test
  • 3.6. Market Restraint Analysis
  • 3.7. Porter's Five Forces Analysis
  • 3.8. PESTLE Analysis
  • 3.9. Pipeline Analysis

Chapter 4. Neuroscience Antibodies and Assays Market: Product Estimates & Trend Analysis

  • 4.1. Neuroscience Antibodies and Assays Market: Product Movement Analysis
  • 4.2. Consumables
    • 4.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.3. Instruments
    • 4.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Neuroscience Antibodies and Assays Market: Technology Estimates & Trend Analysis

  • 5.1. Neuroscience Antibodies and Assays Market: Technology Movement Analysis
  • 5.2. Immunoassays & immunochemistry
    • 5.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.3. Molecular Diagnostics
    • 5.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.4. Clinical Chemistry & other related detection platforms
    • 5.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5. Other emerging / ultrasensitive platforms
    • 5.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Neuroscience Antibodies and Assays Market: End Use Estimates & Trend Analysis

  • 6.1. Neuroscience Antibodies and Assays Market: End Use Movement Analysis
  • 6.2. Academic & Research Institutes
    • 6.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.3. Diagnostics Laboratories
    • 6.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.4. Others
    • 6.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Neuroscience Antibodies and Assays Market: Regional Business Analysis

  • 7.1. Regional Market Snapshot
  • 7.2. North America
    • 7.2.1. North America Neuroscience Antibodies and Assays Market Estimates And Forecast, 2021 - 2033 (USD Million)
    • 7.2.2. U.S.
      • 7.2.2.1. U.S. Neuroscience Antibodies and Assays Market, 2021 - 2033 (USD Million)
      • 7.2.2.2. Key Country Dynamics
      • 7.2.2.3. Regulatory Framework
      • 7.2.2.4. Reimbursement Scenario
      • 7.2.2.5. Competitive Scenario
    • 7.2.3. Canada
      • 7.2.3.1. Canada Neuroscience Antibodies and Assays Market, 2021 - 2033 (USD Million)
      • 7.2.3.2. Key Country Dynamics
      • 7.2.3.3. Regulatory Framework
      • 7.2.3.4. Reimbursement Scenario
      • 7.2.3.5. Competitive Scenario
    • 7.2.4. Mexico
      • 7.2.4.1. Mexico Neuroscience Antibodies and Assays Market, 2021 - 2033 (USD Million)
      • 7.2.4.2. Key Country Dynamics
      • 7.2.4.3. Regulatory Framework
      • 7.2.4.4. Reimbursement Scenario
      • 7.2.4.5. Competitive Scenario
  • 7.3. Europe
    • 7.3.1. Europe Neuroscience Antibodies and Assays Market, 2021 - 2033 (USD Million)
    • 7.3.2. UK
      • 7.3.2.1. UK Neuroscience Antibodies and Assays Market, 2021 - 2033 (USD Million)
      • 7.3.2.2. Key Country Dynamics
      • 7.3.2.3. Regulatory Framework
      • 7.3.2.4. Reimbursement Scenario
      • 7.3.2.5. Competitive Scenario
    • 7.3.3. Germany
      • 7.3.3.1. Germany Neuroscience Antibodies and Assays Market, 2021 - 2033 (USD Million)
      • 7.3.3.2. Key Country Dynamics
      • 7.3.3.3. Regulatory Framework
      • 7.3.3.4. Reimbursement Scenario
      • 7.3.3.5. Competitive Scenario
    • 7.3.4. Spain
      • 7.3.4.1. Spain Neuroscience Antibodies and Assays Market, 2021 - 2033 (USD Million)
      • 7.3.4.2. Key Country Dynamics
      • 7.3.4.3. Regulatory Framework
      • 7.3.4.4. Reimbursement Scenario
      • 7.3.4.5. Competitive Scenario
    • 7.3.5. France
      • 7.3.5.1. France Neuroscience Antibodies and Assays Market, 2021 - 2033 (USD Million)
      • 7.3.5.2. Key Country Dynamics
      • 7.3.5.3. Regulatory Framework
      • 7.3.5.4. Reimbursement Scenario
      • 7.3.5.5. Competitive Scenario
    • 7.3.6. Italy
      • 7.3.6.1. Italy Neuroscience Antibodies and Assays Market, 2021 - 2033 (USD Million)
      • 7.3.6.2. Key Country Dynamics
      • 7.3.6.3. Regulatory Framework
      • 7.3.6.4. Reimbursement Scenario
      • 7.3.6.5. Competitive Scenario
    • 7.3.7. Denmark
      • 7.3.7.1. Denmark Neuroscience Antibodies and Assays Market, 2021 - 2033 (USD Million)
      • 7.3.7.2. Key Country Dynamics
      • 7.3.7.3. Regulatory Framework
      • 7.3.7.4. Reimbursement Scenario
      • 7.3.7.5. Competitive Scenario
    • 7.3.8. Sweden
      • 7.3.8.1. Sweden Neuroscience Antibodies and Assays Market, 2021 - 2033 (USD Million)
      • 7.3.8.2. Key Country Dynamics
      • 7.3.8.3. Regulatory Framework
      • 7.3.8.4. Reimbursement Scenario
      • 7.3.8.5. Competitive Scenario
    • 7.3.9. Norway
      • 7.3.9.1. Norway Neuroscience Antibodies and Assays Market, 2021 - 2033 (USD Million)
      • 7.3.9.2. Key Country Dynamics
      • 7.3.9.3. Regulatory Framework
      • 7.3.9.4. Reimbursement Scenario
      • 7.3.9.5. Competitive Scenario
  • 7.4. Asia Pacific
    • 7.4.1. Asia-Pacific Neuroscience Antibodies and Assays Market, 2021 - 2033 (USD Million)
    • 7.4.2. Japan
      • 7.4.2.1. Japan Neuroscience Antibodies and Assays Market, 2021 - 2033 (USD Million)
      • 7.4.2.2. Key Country Dynamics
      • 7.4.2.3. Regulatory Framework
      • 7.4.2.4. Reimbursement Scenario
      • 7.4.2.5. Competitive Scenario
    • 7.4.3. China
      • 7.4.3.1. China Neuroscience Antibodies and Assays Market, 2021 - 2033 (USD Million)
      • 7.4.3.2. Key Country Dynamics
      • 7.4.3.3. Regulatory Framework
      • 7.4.3.4. Reimbursement Scenario
      • 7.4.3.5. Competitive Scenario
    • 7.4.4. India
      • 7.4.4.1. India Neuroscience Antibodies and Assays Market, 2021 - 2033 (USD Million)
      • 7.4.4.2. Key Country Dynamics
      • 7.4.4.3. Regulatory Framework
      • 7.4.4.4. Reimbursement Scenario
      • 7.4.4.5. Competitive Scenario
    • 7.4.5. South Korea
      • 7.4.5.1. South Korea Neuroscience Antibodies and Assays Market, 2021 - 2033 (USD Million)
      • 7.4.5.2. Key Country Dynamics
      • 7.4.5.3. Regulatory Framework
      • 7.4.5.4. Reimbursement Scenario
      • 7.4.5.5. Competitive Scenario
    • 7.4.6. Thailand
      • 7.4.6.1. Thailand Neuroscience Antibodies and Assays Market, 2021 - 2033 (USD Million)
      • 7.4.6.2. Key Country Dynamics
      • 7.4.6.3. Regulatory Framework
      • 7.4.6.4. Reimbursement Scenario
      • 7.4.6.5. Competitive Scenario
    • 7.4.7. Australia
      • 7.4.7.1. Australia Neuroscience Antibodies and Assays Market, 2021 - 2033 (USD Million)
      • 7.4.7.2. Key Country Dynamics
      • 7.4.7.3. Regulatory Framework
      • 7.4.7.4. Reimbursement Scenario
      • 7.4.7.5. Competitive Scenario
  • 7.5. Latin America
    • 7.5.1. Latin America Neuroscience Antibodies and Assays Market, 2021 - 2033 (USD Million)
    • 7.5.2. Brazil
      • 7.5.2.1. Brazil Neuroscience Antibodies and Assays Market, 2021 - 2033 (USD Million)
      • 7.5.2.2. Key Country Dynamics
      • 7.5.2.3. Regulatory Framework
      • 7.5.2.4. Reimbursement Scenario
      • 7.5.2.5. Competitive Scenario
    • 7.5.3. Argentina
      • 7.5.3.1. Argentina Neuroscience Antibodies and Assays Market, 2021 - 2033 (USD Million)
      • 7.5.3.2. Key Country Dynamics
      • 7.5.3.3. Regulatory Framework
      • 7.5.3.4. Reimbursement Scenario
      • 7.5.3.5. Competitive Scenario
  • 7.6. MEA
    • 7.6.1. MEA Neuroscience Antibodies and Assays Market, 2021 - 2033 (USD Million)
    • 7.6.2. South Africa
      • 7.6.2.1. South Africa Neuroscience Antibodies and Assays Market, 2021 - 2033 (USD Million)
      • 7.6.2.2. Key Country Dynamics
      • 7.6.2.3. Regulatory Framework
      • 7.6.2.4. Reimbursement Scenario
      • 7.6.2.5. Competitive Scenario
    • 7.6.3. Saudi Arabia
      • 7.6.3.1. Saudi Arabia Neuroscience Antibodies and Assays Market, 2021 - 2033 (USD Million)
      • 7.6.3.2. Key Country Dynamics
      • 7.6.3.3. Regulatory Framework
      • 7.6.3.4. Reimbursement Scenario
      • 7.6.3.5. Competitive Scenario
    • 7.6.4. UAE
      • 7.6.4.1. UAE Neuroscience Antibodies and Assays Market, 2021 - 2033 (USD Million)
      • 7.6.4.2. Key Country Dynamics
      • 7.6.4.3. Regulatory Framework
      • 7.6.4.4. Reimbursement Scenario
      • 7.6.4.5. Competitive Scenario
    • 7.6.5. Kuwait
      • 7.6.5.1. Kuwait Neuroscience Antibodies and Assays Market, 2021 - 2033 (USD Million)
      • 7.6.5.2. Key Country Dynamics
      • 7.6.5.3. Regulatory Framework
      • 7.6.5.4. Reimbursement Scenario
      • 7.6.5.5. Competitive Scenario

Chapter 8. Competitive Landscape

  • 8.1. Company Categorization
  • 8.2. Strategy Mapping
    • 8.2.1. NEW PRODUCT LAUNCH
    • 8.2.2. PARTNERSHIPS
    • 8.2.3. ACQUISITION
    • 8.2.4. COLLABORATION
    • 8.2.5. FUNDING
  • 8.3. Key Company Market Share Analysis, 2024
  • 8.4. Company Heat Map Analysis
  • 8.5. Company Profiles
    • 8.5.1. Thermo Fisher Scientific
      • 8.5.1.1. Company Overview
      • 8.5.1.2. Financial Performance
      • 8.5.1.3. Product Benchmarking
      • 8.5.1.4. Strategic Initiatives
    • 8.5.2. Bio-Rad Laboratories, Inc.
      • 8.5.2.1. Company Overview
      • 8.5.2.2. Financial Performance
      • 8.5.2.3. Product Benchmarking
      • 8.5.2.4. Strategic Initiatives
    • 8.5.3. Merck KGaA
      • 8.5.3.1. Company Overview
      • 8.5.3.2. Financial Performance
      • 8.5.3.3. Product Benchmarking
      • 8.5.3.4. Strategic Initiatives
    • 8.5.4. F. Hoffmann-La Roche
      • 8.5.4.1. Company Overview
      • 8.5.4.2. Financial Performance
      • 8.5.4.3. Product Benchmarking
      • 8.5.4.4. Strategic Initiatives
    • 8.5.5. Cell Signaling Technology, Inc.
      • 8.5.5.1. Company Overview
      • 8.5.5.2. Financial Performance
      • 8.5.5.3. Product Benchmarking
      • 8.5.5.4. Strategic Initiatives
    • 8.5.6. BioLegend, Inc.
      • 8.5.6.1. Company Overview
      • 8.5.6.2. Financial Performance
      • 8.5.6.3. Product Benchmarking
      • 8.5.6.4. Strategic Initiatives
    • 8.5.7. Exalenz Bioscience Ltd (meridian bioscience)
      • 8.5.7.1. Company Overview
      • 8.5.7.2. Financial Performance
      • 8.5.7.3. Product Benchmarking
      • 8.5.7.4. Strategic Initiatives
    • 8.5.8. Abcam Plc
      • 8.5.8.1. Company Overview
      • 8.5.8.2. Financial Performance
      • 8.5.8.3. Product Benchmarking
      • 8.5.8.4. Strategic Initiatives
    • 8.5.9. Rockland Immunochemicals, Inc.
      • 8.5.9.1. Company Overview
      • 8.5.9.2. Financial Performance
      • 8.5.9.3. Product Benchmarking
      • 8.5.9.4. Strategic Initiatives
    • 8.5.10. GENSCRIPT
      • 8.5.10.1. Company Overview
      • 8.5.10.2. Financial Performance
      • 8.5.10.3. Product Benchmarking
      • 8.5.10.4. Strategic Initiatives
    • 8.5.11. SANTA CRUZ BIOTECHNOLOGY, INC.
      • 8.5.11.1. Company Overview
      • 8.5.11.2. Financial Performance
      • 8.5.11.3. Product Benchmarking
      • 8.5.11.4. Strategic Initiatives

List of Tables

  • Table 1 List Of Secondary Sources
  • Table 2 List Of Abbreviation
  • Table 3 Global Neuroscience Antibodies and Assays Market, By Region, 2021 - 2033 (USD Million)
  • Table 4 Global Neuroscience Antibodies and Assays Market, By Product, 2021 - 2033 (USD Million)
  • Table 5 Global Neuroscience Antibodies and Assays Market, By Technology, 2021 - 2033 (USD Million)
  • Table 6 Global Neuroscience Antibodies and Assays Market, By End Use, 2021 - 2033 (USD Million)
  • Table 7 North America Neuroscience Antibodies and Assays Market, By Country, 2021 - 2033 (USD Million)
  • Table 8 North America Neuroscience Antibodies and Assays Market, By Product, 2021 - 2033 (USD Million)
  • Table 9 North America Neuroscience Antibodies and Assays Market, By Technology, 2021 - 2033 (USD Million)
  • Table 10 North America Neuroscience Antibodies and Assays Market, By End Use, 2021 - 2033 (USD Million)
  • Table 11 U.S. Neuroscience Antibodies and Assays Market, By Product, 2021 - 2033 (USD Million)
  • Table 12 U.S. Neuroscience Antibodies and Assays Market, By Technology, 2021 - 2033 (USD Million)
  • Table 13 U.S. Neuroscience Antibodies and Assays Market, By End Use, 2021 - 2033 (USD Million)
  • Table 14 Canada Neuroscience Antibodies and Assays Market, By Product, 2021 - 2033 (USD Million)
  • Table 15 Canada Neuroscience Antibodies and Assays Market, By Technology, 2021 - 2033 (USD Million)
  • Table 16 Canada Neuroscience Antibodies and Assays Market, By End Use, 2021 - 2033 (USD Million)
  • Table 17 Mexico Neuroscience Antibodies and Assays Market, By Product, 2021 - 2033 (USD Million)
  • Table 18 Mexico Neuroscience Antibodies and Assays Market, By Technology, 2021 - 2033 (USD Million)
  • Table 19 Mexico Neuroscience Antibodies and Assays Market, By End Use, 2021 - 2033 (USD Million)
  • Table 20 Europe Neuroscience Antibodies and Assays Market, By Country, 2021 - 2033 (USD Million)
  • Table 21 Europe Neuroscience Antibodies and Assays Market, By Product, 2021 - 2033 (USD Million)
  • Table 22 Europe Neuroscience Antibodies and Assays Market, By Technology, 2021 - 2033 (USD Million)
  • Table 23 Europe Neuroscience Antibodies and Assays Market, By End Use, 2021 - 2033 (USD Million)
  • Table 24 UK Neuroscience Antibodies and Assays Market, By Product, 2021 - 2033 (USD Million)
  • Table 25 UK Neuroscience Antibodies and Assays Market, By Technology, 2021 - 2033 (USD Million)
  • Table 26 UK Neuroscience Antibodies and Assays Market, By End Use, 2021 - 2033 (USD Million)
  • Table 27 Germany Neuroscience Antibodies and Assays Market, By Product, 2021 - 2033 (USD Million)
  • Table 28 Germany Neuroscience Antibodies and Assays Market, By Technology, 2021 - 2033 (USD Million)
  • Table 29 Germany Neuroscience Antibodies and Assays Market, By End Use, 2021 - 2033 (USD Million)
  • Table 30 France Neuroscience Antibodies and Assays Market, By Product, 2021 - 2033 (USD Million)
  • Table 31 France Neuroscience Antibodies and Assays Market, By Technology, 2021 - 2033 (USD Million)
  • Table 32 France Neuroscience Antibodies and Assays Market, By End Use, 2021 - 2033 (USD Million)
  • Table 33 Italy Neuroscience Antibodies and Assays Market, By Product, 2021 - 2033 (USD Million)
  • Table 34 Italy Neuroscience Antibodies and Assays Market, By Technology, 2021 - 2033 (USD Million)
  • Table 35 Italy Neuroscience Antibodies and Assays Market, By End Use, 2021 - 2033 (USD Million)
  • Table 36 Spain Neuroscience Antibodies and Assays Market, By Product, 2021 - 2033 (USD Million)
  • Table 37 Spain Neuroscience Antibodies and Assays Market, By Technology, 2021 - 2033 (USD Million)
  • Table 38 Spain Neuroscience Antibodies and Assays Market, By End Use, 2021 - 2033 (USD Million)
  • Table 39 Sweden Neuroscience Antibodies and Assays Market, By Product, 2021 - 2033 (USD Million)
  • Table 40 Sweden Neuroscience Antibodies and Assays Market, By Technology, 2021 - 2033 (USD Million)
  • Table 41 Sweden Neuroscience Antibodies and Assays Market, By End Use, 2021 - 2033 (USD Million)
  • Table 42 Norway Neuroscience Antibodies and Assays Market, By Product, 2021 - 2033 (USD Million)
  • Table 43 Norway Neuroscience Antibodies and Assays Market, By Technology, 2021 - 2033 (USD Million)
  • Table 44 Norway Neuroscience Antibodies and Assays Market, By End Use, 2021 - 2033 (USD Million)
  • Table 45 Denmark Neuroscience Antibodies and Assays Market, By Product, 2021 - 2033 (USD Million)
  • Table 46 Denmark Neuroscience Antibodies and Assays Market, By Technology, 2021 - 2033 (USD Million)
  • Table 47 Denmark Neuroscience Antibodies and Assays Market, By End Use, 2021 - 2033 (USD Million)
  • Table 48 Asia Pacific Neuroscience Antibodies and Assays Market, By Country, 2021 - 2033 (USD Million)
  • Table 49 Asia Pacific Neuroscience Antibodies and Assays Market, By Product, 2021 - 2033 (USD Million)
  • Table 50 Asia Pacific Neuroscience Antibodies and Assays Market, By Technology, 2021 - 2033 (USD Million)
  • Table 51 Asia Pacific Neuroscience Antibodies and Assays Market, By End Use, 2021 - 2033 (USD Million)
  • Table 52 Japan Neuroscience Antibodies and Assays Market, By Product, 2021 - 2033 (USD Million)
  • Table 53 Japan Neuroscience Antibodies and Assays Market, By Technology, 2021 - 2033 (USD Million)
  • Table 54 Japan Neuroscience Antibodies and Assays Market, By End Use, 2021 - 2033 (USD Million)
  • Table 55 China Neuroscience Antibodies and Assays Market, By Product, 2021 - 2033 (USD Million)
  • Table 56 China Neuroscience Antibodies and Assays Market, By Technology, 2021 - 2033 (USD Million)
  • Table 57 China Neuroscience Antibodies and Assays Market, By End Use, 2021 - 2033 (USD Million)
  • Table 58 India Neuroscience Antibodies and Assays Market, By Product, 2021 - 2033 (USD Million)
  • Table 59 India Neuroscience Antibodies and Assays Market, By Technology, 2021 - 2033 (USD Million)
  • Table 60 India Neuroscience Antibodies and Assays Market, By End Use, 2021 - 2033 (USD Million)
  • Table 61 Australia Neuroscience Antibodies and Assays Market, By Product, 2021 - 2033 (USD Million)
  • Table 62 Australia Neuroscience Antibodies and Assays Market, By Technology, 2021 - 2033 (USD Million)
  • Table 63 Australia Neuroscience Antibodies and Assays Market, By End Use, 2021 - 2033 (USD Million)
  • Table 64 Thailand Neuroscience Antibodies and Assays Market, By Product, 2021 - 2033 (USD Million)
  • Table 65 Thailand Neuroscience Antibodies and Assays Market, By Technology, 2021 - 2033 (USD Million)
  • Table 66 Thailand Neuroscience Antibodies and Assays Market, By End Use, 2021 - 2033 (USD Million)
  • Table 67 South Korea Neuroscience Antibodies and Assays Market, By Product, 2021 - 2033 (USD Million)
  • Table 68 South Korea Neuroscience Antibodies and Assays Market, By Technology, 2021 - 2033 (USD Million)
  • Table 69 South Korea Neuroscience Antibodies and Assays Market, By End Use, 2021 - 2033 (USD Million)
  • Table 70 Latin America Neuroscience Antibodies and Assays Market, By Country, 2021 - 2033 (USD Million)
  • Table 71 Latin America Neuroscience Antibodies and Assays Market, By Product, 2021 - 2033 (USD Million)
  • Table 72 Latin America Neuroscience Antibodies and Assays Market, By Technology, 2021 - 2033 (USD Million)
  • Table 73 Latin America Neuroscience Antibodies and Assays Market, By End Use, 2021 - 2033 (USD Million)
  • Table 74 Brazil Neuroscience Antibodies and Assays Market, By Product, 2021 - 2033 (USD Million)
  • Table 75 Brazil Neuroscience Antibodies and Assays Market, By Technology, 2021 - 2033 (USD Million)
  • Table 76 Brazil Neuroscience Antibodies and Assays Market, By End Use, 2021 - 2033 (USD Million)
  • Table 77 Argentina Neuroscience Antibodies and Assays Market, By Product, 2021 - 2033 (USD Million)
  • Table 78 Argentina Neuroscience Antibodies and Assays Market, By Technology, 2021 - 2033 (USD Million)
  • Table 79 Argentina Neuroscience Antibodies and Assays Market, By End Use, 2021 - 2033 (USD Million)
  • Table 80 MEA Neuroscience Antibodies and Assays Market, By Country, 2021 - 2033 (USD Million)
  • Table 81 MEA Neuroscience Antibodies and Assays Market, By Product, 2021 - 2033 (USD Million)
  • Table 82 MEA Neuroscience Antibodies and Assays Market, By Technology, 2021 - 2033 (USD Million)
  • Table 83 MEA Neuroscience Antibodies and Assays Market, By End Use, 2021 - 2033 (USD Million)
  • Table 84 South Africa Neuroscience Antibodies and Assays Market, By Product, 2021 - 2033 (USD Million)
  • Table 85 South Africa Neuroscience Antibodies and Assays Market, By Technology, 2021 - 2033 (USD Million)
  • Table 86 South Africa Neuroscience Antibodies and Assays Market, By End Use, 2021 - 2033 (USD Million)
  • Table 87 Saudi Arabia Neuroscience Antibodies and Assays Market, By Product, 2021 - 2033 (USD Million)
  • Table 88 Saudi Arabia Neuroscience Antibodies and Assays Market, By Technology, 2021 - 2033 (USD Million)
  • Table 89 Saudi Arabia Neuroscience Antibodies and Assays Market, By End Use, 2021 - 2033 (USD Million)
  • Table 90 UAE Neuroscience Antibodies and Assays Market, By Product, 2021 - 2033 (USD Million)
  • Table 91 UAE Neuroscience Antibodies and Assays Market, By Technology, 2021 - 2033 (USD Million)
  • Table 92 UAE Neuroscience Antibodies and Assays Market, By End Use, 2021 - 2033 (USD Million)
  • Table 93 Kuwait Neuroscience Antibodies and Assays Market, By Product, 2021 - 2033 (USD Million)
  • Table 94 Kuwait Neuroscience Antibodies and Assays Market, By Technology, 2021 - 2033 (USD Million)
  • Table 95 Kuwait Neuroscience Antibodies and Assays Market, By End Use, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Market summary
  • Fig. 4 Market segmentation & scope
  • Fig. 5 Market size and growth prospects
  • Fig. 6 Global neuroscience antibodies and assays market- Key market driver analysis
  • Fig. 7 Global neuroscience antibodies and assays market - Key market restraint analysis
  • Fig. 8 Penetration & growth prospect mapping
  • Fig. 9 Global neuroscience antibodies and assays market - Porter's analysis
  • Fig. 10 Global neuroscience antibodies and assays market - PESTEL analysis
  • Fig. 11 Global neuroscience antibodies and assays market Product outlook key takeaways
  • Fig. 12 Global neuroscience antibodies and assays market: Product movement analysis
  • Fig. 13 Consumables market estimates, 2021 - 2033 (USD Million)
  • Fig. 14 Instruments market estimates, 2021 - 2033 (USD Million)
  • Fig. 15 Global neuroscience antibodies and assays market technology outlook key takeaways
  • Fig. 16 Global neuroscience antibodies and assays market: technology movement analysis
  • Fig. 17 Immunoassays & immunochemistry market estimates, 2021 - 2033 (USD Million)
  • Fig. 18 Molecular diagnostics market estimates, 2021 - 2033 (USD Million)
  • Fig. 19 Proteomics/metabolomics market estimates, 2021 - 2033 (USD Million)
  • Fig. 20 Imaging-based biomarker assessment market estimates, 2021 - 2033 (USD Million)
  • Fig. 21 Global neuroscience antibodies and assays market end use outlook key takeaways
  • Fig. 22 Global neuroscience antibodies and assays market: end use movement analysis
  • Fig. 23 Academic & Research Institutes and diagnostics laboratories market estimates, 2021 - 2033 (USD Million)
  • Fig. 24 Pharmaceutical & biotechnology firms market estimates, 2021 - 2033 (USD Million)
  • Fig. 25 Other End-users market estimates, 2021 - 2033 (USD Million)
  • Fig. 26 Regional marketplace: Key takeaways
  • Fig. 27 Global Neuroscience Antibodies and Assays market: Regional movement analysis
  • Fig. 28 North America Neuroscience Antibodies and Assays market, 2021 - 2033 (USD Million)
  • Fig. 29 U.S. neuroscience antibodies and assays market, 2021 - 2033 (USD Million)
  • Fig. 30 Canada neuroscience antibodies and assays market, 2021 - 2033 (USD Million)
  • Fig. 31 Mexico neuroscience antibodies and assays market, 2021 - 2033 (USD Million)
  • Fig. 32 Europe neuroscience antibodies and assays market, 2021 - 2033 (USD Million)
  • Fig. 33 UK neuroscience antibodies and assays market, 2021 - 2033 (USD Million)
  • Fig. 34 Germany neuroscience antibodies and assays market, 2021 - 2033 (USD Million)
  • Fig. 35 France neuroscience antibodies and assays market, 2021 - 2033 (USD Million)
  • Fig. 36 Spain neuroscience antibodies and assays market, 2021 - 2033 (USD Million)
  • Fig. 37 Italy neuroscience antibodies and assays market, 2021 - 2033 (USD Million)
  • Fig. 38 Denmark neuroscience antibodies and assays market, 2021 - 2033 (USD Million)
  • Fig. 39 Sweden neuroscience antibodies and assays market, 2021 - 2033 (USD Million)
  • Fig. 40 Norway neuroscience antibodies and assays market, 2021 - 2033 (USD Million)
  • Fig. 41 Asia Pacific neuroscience antibodies and assays market, 2021 - 2033 (USD Million)
  • Fig. 42 Japan neuroscience antibodies and assays market, 2021 - 2033 (USD Million)
  • Fig. 43 China neuroscience antibodies and assays market, 2021 - 2033 (USD Million)
  • Fig. 44 India neuroscience antibodies and assays market, 2021 - 2033 (USD Million)
  • Fig. 45 South Korea neuroscience antibodies and assays market, 2021 - 2033 (USD Million)
  • Fig. 46 Australia neuroscience antibodies and assays market, 2021 - 2033 (USD Million)
  • Fig. 47 Thailand neuroscience antibodies and assays market, 2021 - 2033 (USD Million)
  • Fig. 48 Latin America neuroscience antibodies and assays market, 2021 - 2033 (USD Million)
  • Fig. 49 Brazil neuroscience antibodies and assays market, 2021 - 2033 (USD Million)
  • Fig. 50 Argentina neuroscience antibodies and assays market, 2021 - 2033 (USD Million)
  • Fig. 51 MEA neuroscience antibodies and assays market, 2021 - 2033 (USD Million)
  • Fig. 52 South Africa neuroscience antibodies and assays market, 2021 - 2033 (USD Million)
  • Fig. 53 Saudi Arabia neuroscience antibodies and assays market, 2021 - 2033 (USD Million)
  • Fig. 54 UAE neuroscience antibodies and assays market, 2021 - 2033 (USD Million)
  • Fig. 55 Kuwait neuroscience antibodies and assays market, 2021 - 2033 (USD Million)
  • Fig. 56 Strategy framework